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INTRODUCTION: Ovarian cancer is generally diagnosed at advanced stages of the disease; therefore, poor prognoses are typical. 
The development of tumor markers is thus of utmost importance. Prostasin is a protease that in normal tissues is highly expressed 
only in the prostate gland and seminal fluid. A previous study showed that prostasin is highly overexpressed in ovarian cancer cell 
lines. This study sought to evaluate the expression of prostasin in ovarian cancer.  
METHODS: Fresh tumor samples of ovarian epithelial cancer (n: 12) were analyzed for expression of prostasin mRNA (messen-
ger ribonucleic acid) by conventional and real time quantitative PCR (polymerase chain reaction). As a standard control, a normal 
prostate sample was analyzed. 
RESULTS: Using conventional PCR, prostasin was detected in all but one sample. Using quantitative PCR, prostasin was over-
expressed in all but one of the samples as compared to the control (prostate). 
CONCLUSIONS: These findings indicate that prostasin is overexpressed in many epithelial ovarian cancers. Further studies of 
prostasin as a potential biomarker for this disease are warranted.  
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INTRODUCTION 
Ovarian cancer is the third most common cause of 
cancer-related death in women worldwide, and in many parts 
of the world ovarian cancer is the most common cause of 
gynecological cancer-related mortality.1,2 
The dismal prognosis associated with ovarian cancer 
is mainly due to the fact that the majority of patients are 
diagnosed in the advanced stages of the disease. In earlier 
stages, the 5-year overall survival rate is around 90%, 
whereas in more advanced stages it is below 30%.3 There is 
thus a need for early detection strategies in order to increase 
the number of patients who can be diagnosed during the 
curable stages of the disease.
At present, tumor markers for early ovarian cancer with 
sufficient sensitivity and specificity for screening are not 
available.4-6 However, during the last few years, several 
promising candidate proteins have been identified.7-10 
Although many proteins, alone or in combination, show 
promise as potential tumor markers, much work remains 
in order to validate such findings. Prostasin has been 
demonstrated to be overexpressed in ovarian cancer cell lines 
and has been detected in the serum of ovarian cancer patients 
at levels significantly higher than that of normal controls.11 
In this study, we investigated the expression of prostasin 
mRNA in ovarian cancer in order to further corroborate these 
findings and to generate more data on prostasin as a potential 
biomarker in ovarian cancer.
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METHODS
From September 2003 to September 2005, fresh tumor 
samples were collected from 30 patients undergoing 
abdominal surgery for ovarian tumor diagnosis and 
treatment in the following hospitals located in Porto Alegre, 
Brazil: Hospital São Lucas, Hospital Fêmina and Hospital 
Conceição. Eligibility criteria included no previous cancer 
diagnosis or treatment. All patients signed informed consent 
before the surgery. This study was approved by the Ethics 
Committees of each hospital mentioned above.
The specimens were collected during the surgical 
procedures for ovarian resection or biopsy and stored at -70 
oC. Samples from benign cysts and non-epithelial ovarian 
cancers were not used. Normal prostatic tissue was used 
as a control and as a physiological reference for prostasin 
expression. The study was carried out in accordance with the 
ethical standards of the local ethics and scientific committees 
and the Helsinki Declaration.  
Reverse Transcription – Polymerase Chain Reaction 
(RT-PCR)
Total RNA was extracted using TRIZOL® reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer’s instructions.
The cDNA was generated by using SuperScript II Rnase 
H-
 
 reverse transcriptase (Invitrogen Life Technologies, 
Carlsbad, CA, USA). The total mixture contained 
RNA, oligo dT, MgCl2, enzyme buffer, dithiothreitol, 
dideoxynucleotides, SuperScript II and  RNAse inhibitor 
(RNase Out TM Ribonuclease Inhibitor; Invitrogen Life 
Technologies, Carlsbad, CA, USA). One tube containing 
RNA, dideoxynucleotides and oligo dT was initially 
incubated at 65oC for 5 minutes in a thermocycler (iCycler, 
BioRad, Hercules, CA, USA) and placed on ice for one 
minute. After that, the reverse transcription reaction 
components cited above were added and incubated at 42oC 
for 50 minutes. The mixture was heated at 70oC for 15 
minutes and denatured in ice for 1 minute. Finally, RNAse 
H was added to the mixture, which was incubated at 37oC for 
20 minutes. The cDNA was stored at -20oC.
The RT-PCR reaction was performed by using 
primer sets specific for prostasin (forward primer: 
5´-ACTTGAGCCACTCCTTCCTTCAG-3´; reverse 
primer: 5´- CTGATGGTCCCAAAAAGCACAC-3´) 11 
and the housekeeping gene ß-globin (forward primer: 
5`-GAAGAGCCAAGGACAGGTAC-3`; reverse primer 
5`-CAACTTCATCCACTGTCACC-3` (268 base pair).  The 
total mixture for the PCR  contained 2.5 µl of cDNA, 10 
pmol of each primer, 200 pmol of dideoxynucleosides, 1.5 
mM of MgCl2 , 10X enzyme buffer, 2 U of Taq Polymerase 
and deionized water. PCR amplification in an automatic 
thermocycler (MJ Research PT150CA, USA) was performed 
with 31 cycles at 96oC for 1 minute, 60oC for 1 minute and 
72oC for 10 minutes. A mixture without DNA was used 
as a negative control to rule out contamination, and the 
amplification result was verified using 3.5% agarose gel 
electrophoresis and an ultraviolet transilluminator (201 
Macrovue Transluminator LKB, Bromma, Sweden).
Real-Time RT-PCR
To evaluate the relative expression of the prostasin gene 
in the tumor samples, the quantitative RT-PCR technique 
was performed. Reverse transcription of the total RNA was 
carried out with random hexamers, reverse transcriptase, 
MgCl2, and dideoxynucleotides. For real-time assessment 
of prostasin gene expression, Taqman chemistry was 
employed; an amplification reaction mix was generated 
that contained Taq enzyme buffer, dideoxynucleotides, 
Hot-Start Taq DNA polymerase (AmpliTaq, Applied 
Biosystems, Foster, CA, USA) and MgCl2, according to 
the manufacturer´s instructions. Fifty nanograms of cDNA 
was added to this mixture in addition to the specific human 
prostasin or b-actin primers/probes assembled in separate 
wells (Assays-on-Demand®, Applied Biosystems, Foster, 
CA, USA). The probes were labeled either with FAM or 
VIC fluorophores. The cDNAs were than amplified by 
denaturation for 10 minutes at 95oC, followed by 50 two-step 
cycles of denaturation at 95oC for 15 seconds and annealing-
extension at 60oC for 60 seconds. The PCR efficiency was 
examined by serially diluting the template cDNA (100 
ng, 50 ng, 25 ng, 12.5 ng and 0 ng). The Ct values and 
concentrations of the serial dilutions were plotted, and linear 
regression analysis was used to obtain the determination 
coefficient (r2) of the reaction; the latter should be at least 
98% to enable relative expression analysis using the DDCt 
Method.  Each cDNA was amplified in triplicate, and a 
no-RT mRNA sample was included in every plate for 
background correction.12 For each test sample, prostasin 
and b-actin were amplified in parallel. ß-actin was used to 
normalize the quantity of RNA and to adjust the efficiency 
of the RT reaction. The changes in fluorescence for every 
cycle were monitored in a thermocycler (ABI7500, Applied 
Biosystems, Foster, CA, USA), and the relative expression 
was calculated as described by Livak et al.13 The relative 
amount of PCR product generated from each primer/probe 
set was determined on the basis of the CT value. The CT value 
was then subtracted from that of each target gene to obtain 
a DCT value. The difference between the DCT values of the 
samples for the target gene and the CT value of a calibrator 
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(prostate) was determined. The relative quantitative value 
was expressed as 2-DDCT. Therefore, the prostasin expression 
for each sample was presented as the fold change relative to 
the calibrator tissue, in this case prostate.
RESULTS 
Patient characteristics
In total, 30 patients were screened, and 12 were included. 
Among the 18 excluded samples, 10 were benign cysts, 3 
were non-epithelial ovarian cancers (thecoma, metastatic 
melanoma and Krukenberg tumor) and the quality of the 
RNA in 5 of the samples was not sufficient for analysis. Of 
the 12 patients included, 90% had advanced disease (clinical 
stage III and IV). The mean age was 61.2 years (29-83). 
RT-PCR
Positive RT-PCR results for prostasin were obtained in 
11 of the 12 samples.
Real-time RT-PCR. Efficiency and validation 
calculation
As explained above, the PCR efficiency was examined 
by serial dilution by a factor of 2. In this case, a difference 
of 1 amplification cycle (CT ) should be observed. This was 
exactly the result we obtained, generating determination 
coefficients of 0.9902 and 0.9985.
Real-time RT-PCR
The prostate gland is the human tissue with the highest 
prostasin expression. Therefore, prostate tissue was used as 
a control and as a physiological reference. All but one of the 
epithelial samples showed a significant relative increase in 
prostasin expression. The highest level was 3.30-fold, higher 
and the mean was about 2-fold higher than the control. 
DISCUSSION 
Prostasin was first identified in 1994 when Yu et al. 
isolated it from seminal fluid and demonstrated localization 
in epithelial cells and the ducts of the prostate using 
radioimmunoassay and immunohistochemical techniques.14
Prostasin is a 40-kDa trypsin-like proteinase.14 The 
catalytic triad that is essential for the enzymatic activity of 
prostasin is a histidine, aspartic acid, and serine sequence. 
The sequences around the active sites of serine proteinases 
are highly conserved.15
Although the biological and physiological roles of 
prostasin are not known at present, the high levels of 
prostasin in the prostate and seminal fluid (over 20-fold 
higher than any other tissue examined) suggest it may play 
an important physiological role in these locations. Other 
data also show that prostasin is present at low levels in other 
tissues, such as the lung, kidney, liver, bronchi, colon and 
salivary glands, indicating that it may have roles in other 
biological processes as well.14 In normal ovarian tissue, 
prostasin is not highly expressed.11,15
Prostasin’s role in cancer is unclear, but there is 
evidence indicating that it may be related to tumor promoter 
mechanisms,16 as well as tumor suppressor mechanisms.17-19 
Recently, other data has also shown that prostasin is involved 
in proteolytic cleavage of the extracellular domain of EGFR 
(epithelial growth factor receptor), causing a constitutively 
phosphorylated receptor20 that could potentially participate 
in fueling tumor growth. 
Prostasin was first studied as a potential marker for 
prostate cancer by Laribi et al. They found that all 86 of 
their blood samples from normal controls failed to amplify 
prostasin PCR products, whereas blood samples from 35 
of 96 (36%) prostate cancer patients were positive. Of the 
metastatic patients, 63% (17/27) were positive, but only 26% 
(18/69) of patients with local tumors were positive.20
The potential use of prostasin as a marker of ovarian 
cancer has been suggested in a study demonstrating that 
prostasin mRNA expression ranged from 120- to 410-fold 
higher in ovarian cancer cell lines than normal ovarian 
cell lines. The abnormal expression of prostasin in these 
cell lines was further confirmed at the protein level by 
immunostaining. Since the expression of prostasin was 
so markedly different between normal and malignant 
ovarian cells, the serum prostasin levels were investigated 
in patients with and without ovarian cancer. The prostasin 
levels were higher in the serum of ovarian cancer patients 
than in controls. Moreover, the serum prostasin levels were 
significantly reduced after surgery in the vast majority of the 
cases studied.11 
Our study is the first to perform quantification of mRNA 
prostasin expression in fresh-frozen ovarian cancer tissue 
samples. The data corroborate that prostasin is overexpressed 
in many ovarian cancers and that expression is significantly 
higher in malignant than normal tissue (control). Thus, 
further studies exploring the use of prostasin as a potential 
biomarker in ovarian cancer are warranted.
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